Company CorMedix Inc.

CRMD

US21900C3088

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:11:52 29/04/2024 pm IST			5-day change	1st Jan Change
5.27 ^USD	-0.75%		+0.17%	+40.67%

15/04	CorMedix's DefenCath Now Commercially Available For US Inpatient Use	MT
15/04	CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	CI

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Number of employees: 83

Managers	Title	Age	Since
Joseph Todisco CEO	Chief Executive Officer	48	18/22/18
Mathew David DFI	Director of Finance/CFO	47	11/20/11
Tushar Mukherjee CTO	Chief Tech/Sci/R&D Officer	-	01/22/01
Beth Zelnick Kaufman LAW	General Counsel	-	12/12
Erin Mistry PRN	Corporate Officer/Principal	43	01/20/01
Frank Raffaele PRN	Corporate Officer/Principal	-	12/22/12
Donna Ucci PRN	Corporate Officer/Principal	-	12/22/12
Elizabeth Masson-Hurlburt PRN	Corporate Officer/Principal	45	01/18/01

Members of the board	Title	Age	Since
Myron Kaplan CHM	Chairman	79	27/16/27
Steven Lefkowitz DFI	Director of Finance/CFO	68	15/11/15
Alan Dunton BRD	Director/Board Member	70	01/19/01
Janet Dillione BRD	Director/Board Member	65	06/15/06
Joseph Todisco CEO	Chief Executive Officer	48	18/22/18
Gregory Duncan BRD	Director/Board Member	59	02/20/02
Robert Stewart BRD	Director/Board Member	56	13/23/13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	54,981,102	54,425,049 ( 98.99 %)	0	98.99 %
Stock B	0	181,622	0	0

Name	Equities	%	Valuation
BlackRock Advisors LLC 6.129 %	3,369,714	6.129 %	14 M $
NOMURA HOLDINGS, INC. 5.359 %	2,946,552	5.359 %	12 M $
Vanguard Fiduciary Trust Co. 5.139 %	2,825,335	5.139 %	12 M $
Elliott Investment Management LP 2.820 %	1,550,523	2.820 %	7 M $
Geode Capital Management LLC 2.108 %	1,158,808	2.108 %	5 M $
STATE STREET CORPORATION 1.952 %	1,073,134	1.952 %	5 M $
Marshall Wace LLP 0.8421 %	463,006	0.8421 %	2 M $
Northern Trust Investments, Inc.(Investment Management) 0.7481 %	411,307	0.7481 %	2 M $
Joseph Todisco 0.6417 %	352,839	0.6417 %	1 M $
Millennium Management LLC 0.5243 %	288,254	0.5243 %	1 M $

CorMedix, Inc.

300 Connell Drive Suite 4200

07922, Berkeley Heights

+908 517 9500

http://www.cormedix.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.31 USD

Average target price

13 USD

Spread / Average Target

+144.82%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CORMEDIX INC.	+40.67%	292M
MERCK KGAA	+4.06%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-14.44%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+41.60%	4.5B
YUHAN CORPORATION	+5.96%	3.85B
INDIVIOR PLC	+23.46%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-19.32%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.04%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.97%	1.96B

Specialty & Advanced Pharmaceuticals